Invention:
This technology assists with the inhibition of HMGB1 to decrease the body’s inflammatory response, which occurs when the HMGB1 protein binds to DNA and TLR4. By decreasing HMGB1 binding to DNA, cell inflammation can be significantly reduced, thus preventing further cell damage. This technology can be used in a large spectrum of diseases, such as: diabetic complications, hypertension, systemic inflammation, acute chronic heart, kidney, and liver diseases.
Background:
Chronic cell inflammation plays a pivotal role in cell damage and inflammation to the body’s cells is a major side effect in many different diseases. Current technologies that aim at trying to reduce cell inflammation are to supplement the body with foods that have anti-inflammatory properties, as well as the use of infrared led exposure. However, oftentimes eating these certain foods may not be sufficient enough to repair excessive inflammation. Infrared light exposure can cause numerous side effects, such as irritability and insomnia. By inhibiting HMGB1 using peptide-based modulators, the body’s natural response to trigger inflammation can be decreased. This new technology prohibits the release of pro-apoptotic and pro-inflammatory proteins, which typically occur when HMGB1 binds to DNA and TLR4.
Applications:
- Treatment of pulmonary arterial hypertension (PAH) in heart disease
- Used to treat cell inflammation and damage in diseases including but not limited to:
- Diabetic complications
- Hypertension
- Systemic inflammation
- Acute and chronic heart disease
- Kidney and liver diseases
Advantages:
- Wide variety of uses
- Significantly less side effects than other technologies in the field
- Significant decrease in further cell damage
- Is a proactive approach, as opposed to reactive
